Breast cancer and NSAID use: a meta-analysis

Abstract

Recent epidemiological studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of several cancers including breast cancer. This meta-analysis examined the studies on NSAID use and breast cancer. The estimators of relative risk and associated variances, which have been adjusted for the greatest number of confounders, were abstracted and included in the meta-analysis. Combined estimators of relative risk (RR) were calculated using either fixed or random effect models. Meta-analyses were performed on 6 cohort studies (number of cases ranged from 14 to 2414) and 8 case-control studies (number of cases ranged from 252 to 5882). The combined estimate of relative risk was 0.82 (95% confidence interval [CI] = 0.75-0.89). The combined estimate for cohort studies was 0.78 (95% CI = 0.62-0.99) and was 0.87 (95% CI = 0.84-0.91) for case-control studies. The findings of this meta-analysis suggest that NSAID use may be associated with a small decrease in the risk of breast cancer. However, the available data are insufficient to estimate the dose-response effect for duration and frequency of use of any particular types of NSAID.

References 34

1. 1.

   Baron J. A. Aspirin and cancer. Prev Med. 1995;24(2):121-124.

   Not in our library10.1006/pmed.1995.1023

2. 2.

   Begg C. B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.

   Not in our library

3. 3.

   Carter C. A., Milholland R. J., Shea W., Ip M. M. Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res. 1983;43(8):3559-3562.

   Not in our library

4. 4.

   Coogan P. F., Rao S. R., Rosenberg L., Palmer J. R., Strom B. L., Zauber A. G., Stolley P. D., Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med. 1999;29(2):72-76.

   Not in our library10.1006/pmed.1999.0518

5. 5.

   DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.

   Not in our library10.1016/0197-2456(86)90046-2

6. 6.

   Dinse G. E., Umbach D. M., Sasco A. J., Hoel D. G., Davis D. L. Unexplained increases in cancer incidence in the United States from 1975 to 1994: possible sentinel health indicators? Annu Rev Public Health. 1999;20:173-209.

   Not in our library10.1146/annurev.publhealth.20.1.173

7. 7.

   Egan K. M., Stampfer M. J., Giovannucci E., Rosner B. A., Colditz G. A. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996;88(14):988-993.

   Not in our library10.1093/jnci/88.14.988

8. 8.

   Friedman G. D., Ury H. K. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst. 1980;65(4):723-733.

   Not in our library10.1093/jnci/65.4.723

9. 9.

   Gridley G., McLaughlin J. K., Ekbom A., Klareskog L., Adami H. O., Hacker D. G., Hoover R., Fraumeni J. F. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85(4):307-311.

   Not in our library10.1093/jnci/85.4.307

10. 10.

    Harris R. E., Alshafie G. A., Abou-Issa H., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;60(8):2101-2103.

    Not in our library

11. 11.

    Harris R. E., Kasbari S., Farrar W. B. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6(1):71-73.

    Not in our library

12. 12.

    Harris R. E., Namboodiri K. K., Farrar W. B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996;7(2):203-205.

    Not in our library10.1097/00001648-199603000-00017

13. 13.

    Harris R. E., Namboodiri K., Stellman S. D., Wynder E. L. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med. 1995;24(2):119-120.

    Not in our library10.1006/pmed.1995.1022

14. 14.

    Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90(6):455-460.

    Not in our library10.1093/jnci/90.6.455

15. 15.

    Kelsey J. L., Gammon M. D., John E. M. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36-47.

    Not in our library10.1093/oxfordjournals.epirev.a036115

16. 16.

    Lala P. K., Al-Mutter N., Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer. 1997;73(3):371-380.

    Not in our library10.1002/(sici)1097-0215(19971104)73:3<371::aid-ijc12>3.0.co;2-g

17. 17.

    Langman M. J., Cheng K. K., Gilman E. A., Lancashire R. J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320(7250):1642-1646.

    Not in our library10.1136/bmj.320.7250.1642

18. 18.

    Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature. 1978;272(5654):634-636.

    Not in our library10.1038/272634a0

19. 19.
    Mechanism of inhibition of tumour growth by aspirin and indomethacin · 1978

    No notice
20. 20.

    Madigan M. P., Ziegler R. G., Benichou J., Byrne C., Hoover R. N. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst. 1995;87(22):1681-1685.

    Not in our library10.1093/jnci/87.22.1681

21. 21.

    McCormick D. L., Wilson A. M. Combination chemoprevention of rat mammary carcinogenesis by indomethacin and butylated hydroxytoluene. Cancer Res. 1986;46(8):3907-3911.

    Not in our library

22. 22.

    Mellemkjaer L., Linet M. S., Gridley G., Frisch M., Møller H., Olsen J. H. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32A(10):1753-1757.

    Not in our library10.1016/0959-8049(96)00210-9

23. 23.

    Neugut A. I., Rosenberg D. J., Ahsan H., Jacobson J. S., Wahid N., Hagan M., Rahman M. I., Khan Z. R., Chen L., Pablos-Mendez A. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev. 1998;7(10):869-873.

    Not in our library

24. 24.

    Paganini-Hill A., Chao A., Ross R. K., Henderson B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299(6710):1247-1250.

    Not in our library10.1136/bmj.299.6710.1247

25. 25.

    Robertson F. M., Parrett M. L., Joarder F. S., Ross M., Abou-Issa H. M., Alshafie G., Harris R. E. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett. 1998;122(1-2):165-175.

    Not in our library10.1016/s0304-3835(97)00387-x

26. 26.

    Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med. 1995;24(2):107-109.

    Not in our library10.1006/pmed.1995.1018

27. 27.

    Rosenberg L., Palmer J. R., Zauber A. G., Warshauer M. E., Stolley P. D., Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991;83(5):355-358.

    Not in our library10.1093/jnci/83.5.355

28. 28.

    Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5(2):138-146.

    Not in our library10.1097/00001648-199403000-00003

29. 29.
    Nested case–control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage · 2000

    No notice
30. 30.

    Symmons D. P. Neoplasia in rheumatoid arthritis. J Rheumatol. 1988;15(9):1319-1322.

    Not in our library

31. 31.

    Thompson H. J., Briggs S., Paranka N. S., Piazza G. A., Brendel K., Gross P. H., Sperl G. J., Pamukcu R., Ahnen D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst. 1995;87(16):1259-1260.

    Not in our library

32. 32.

    Thun M. J., Namboodiri M. M., Calle E. E., Flanders W. D., Heath C. W. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53(6):1322-1327.

    Not in our library

33. 33.

    Wun L. M., Feuer E. J., Miller B. A. Are increases in mammographic screening still a valid explanation for trends in breast cancer incidence in the United States? Cancer Causes Control. 1995;6(2):135-144.

    Not in our library10.1007/bf00052774

34. 34.

    van Aswegen C., Dirksen van Schalkwyk J. C., Roux L. J., Becker P. J., Du Plessis D. J. A novel study on the effect of acetylsalicylic acid on the binding capacity of estrogen receptors from MCF-7 cells. Clin Physiol Biochem. 1992;9(4):145-149.

    Not in our library

Cited by papers we hold 6

• Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer · 2018
  Not checked
• Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis · 2015
  No notice
• Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer · 2005
  Not checked
• COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ · 2004
  No notice
• Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis · 2004
  No notice
• A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin · 2003
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.